Bradley A McGregor
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bradley A McGregor as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:45 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04724018 · Sacituzumab Govitecan Plus EV in Metastatic UCDana-Farber Cancer Institute · recruiting · Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter · principal investigator
- Ph2NCT04040725 · Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 OverexpressionDana-Farber Cancer Institute · withdrawn · Bladder Cancer · principal investigator
- Ph2NCT03333616 · Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsDana-Farber Cancer Institute · active not recruiting · Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:45 UTC. The ranking covers the 200 most relevant of 34 PubMed records, and a shared surname and initials can bring in a namesake. All 34 on PubMed
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.J Clin Oncol · 2019549 citationsRCR 20.8
- Cognitive-behavioral stress management reduces serum cortisol by enhancing benefit finding among women being treated for early stage breast cancer.Psychosom Med · 2000195 citationsRCR 6.0
- 186 citationsRCR 36.4
- Cognitive-behavioral stress management increases benefit finding and immune function among women with early-stage breast cancer.J Psychosom Res · 2004154 citationsRCR 4.3
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nat Commun · 2021152 citationsRCR 7.1
- 125 citationsRCR 4.7
- Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).J Clin Oncol · 202094 citationsRCR 3.0
- SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.J Clin Oncol · 201588 citationsRCR 2.4
- 87 citationsRCR 4.8
- The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.Ann Oncol · 202483 citationsRCR 9.5